June 16, 2020
2 min watch
Save
VIDEO: Drop formulation effective against Demodex blepharitis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Richard L. Lindstrom, MD, discusses the phase 2a Mars study results of TP-03 for the treatment of Demodex blepharitis, presented at the virtual Association for Research in Vision and Ophthalmology meeting.
The study showed statistically significant improvements in both collarette score and mite eradication.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Lindstrom reports he is on the medical advisory board of Tarsus, the company developing TP-03.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.